한화 실적 급가속 분석과 주가 전망 투자 전략 한화는 매수 의견이며 현재 주가가 평균 목표가 대비 크게 낮다. 분기 실적에서 매출과 영업이익이 크게 늘어 저평가와 실적 모멘텀이 재평가로 이어질 가능성이 있다. 2026년 10월 26일 Korean
Woori Financial Group Stock Slows Ahead of Earnings: Key Insight Woori Financial looks undervalued: earnings rose YoY with strong margins, consensus Buy and targets up, but cyber and governance risks plus non interest income volatility could delay rerating. 2026년 10월 23일 English
Hanwha Group Earnings Rally: Revenue and Profit Surge Hanwha Group is a Buy: revenue +48.8% YoY and operating profit +80.7% YoY, with net profit +504.5% YoY, supporting upside despite headline risks. 2026년 10월 16일 English
SK Holdings Earnings Surge With Low PER: Buy the Dips SK Holdings is a Buy: revenue up 39.9% and net profit up 989.3% YoY, yet the stock trades at a very low leading PER of 3.7 with analysts seeing about 47% upside; main risk is profit spike reverses. 2026년 10월 07일 English
POSCO Holdings Earnings Rebound – Forward Discount Insight POSCO Holdings earns rebounded sharply: net profit up 126.7% YoY and operating profit up 38.3% YoY, while analysts rate it Buy with wide upside targets; re-rating hinges on margin stability and lithium optionality. 2026년 10월 06일 English
SK Hynix Earnings Soar 256.8% YoY: Upside Case Ahead SK Hynix is rated Buy as AI-driven memory demand fuels explosive revenue and profit growth, with very high margins, strong analyst consensus, and upside despite cycle and margin-compression risks. 2026년 10월 06일 English
Shinhan Financial Group Earnings Stay Strong – What It Means Shinhan Financial Group shows strong earnings growth and favorable valuation with a Buy consensus, but rising credit and cybersecurity operational risks may still threaten returns. 2026년 10월 05일 English
Hanwha Group Stock Jumps as Profits Soar: Value Insight Hanwha Group looks undervalued: revenue +48.8% YoY, operating profit +80.7% YoY, net income +504.5% YoY, yet forward PER is 4.7; analysts rate Buy with targets around 191,097. 2026년 10월 05일 English
한화 실적 급증 기반 주가 전망 분석 투자 전략 한화 투자의견 매수로, 2026년 6월 분기 매출 48.8% 영업이익 80.7% 순이익 504.5% 급증하며 이익 레버리지가 확인됨. 선행 PER 4.7 낮아 목표가 191097원 여력 존재. 2026년 10월 05일 Korean
Samsung Biologics Q2 Earnings Climb – More Upside Than Valuation Signals Samsung Biologics has Buy consensus and strong results: revenue up 30%, operating profit up 23%, net income up 33%, with margins at 54% gross and 44% operating, while the stock trades below the average target of about 1.97M won. 2026년 10월 01일 English
